Biohaven Past Earnings Performance
Past criteria checks 0/6
Biohaven's earnings have been declining at an average annual rate of -34.2%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-34.2%
Earnings growth rate
-10.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -254.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Biohaven's Revenue Path: SCA And Obesity Therapies
Nov 29Biohaven: A Complicated Tale
Oct 11Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst
Sep 23Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Jul 26Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
May 18We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate
Apr 06
Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
Mar 01Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)
Feb 28Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)
Dec 08Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Dec 04Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True
Sep 27Biohaven's Valuation Challenge: Weighing Potential Against Setbacks
Aug 28Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Jul 22Biohaven: A Promising Investment In Innovative Neurological Therapies
Jun 14Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache
Jun 06Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?
Apr 06Biohaven's spinal muscular atrophy therapy gets FDA fast track status
Feb 21Biohaven Ltd: Assessing The Spinoff
Dec 07Biohaven Non-GAAP EPS of -$1.25
Nov 09Revenue & Expenses Breakdown
How Biohaven makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -804 | 86 | 763 |
| 30 Jun 24 | 0 | -747 | 80 | 701 |
| 31 Mar 24 | 0 | -517 | 76 | 466 |
| 31 Dec 23 | 0 | -408 | 63 | 373 |
| 30 Sep 23 | 0 | -465 | 120 | 272 |
| 30 Jun 23 | 0 | -431 | 120 | 229 |
| 31 Mar 23 | 0 | -544 | 126 | 327 |
| 31 Dec 22 | 0 | -570 | 131 | 333 |
| 30 Sep 22 | 0 | -421 | 64 | 342 |
| 30 Jun 22 | 0 | -407 | 57 | 336 |
| 31 Mar 22 | 0 | -257 | 47 | 205 |
| 31 Dec 21 | 0 | -214 | 37 | 181 |
Quality Earnings: BHVN is currently unprofitable.
Growing Profit Margin: BHVN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BHVN is unprofitable, and losses have increased over the past 5 years at a rate of 34.2% per year.
Accelerating Growth: Unable to compare BHVN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BHVN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: BHVN has a negative Return on Equity (-254.53%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:29 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biohaven Ltd. is covered by 16 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| Thomas Shrader | BTIG |